Small molecule modulators of the BTB domain of Keap1

Patent metadata

Field	Value
Publication number	US-11479539-B2
Application number	US-201816955403-A
Country	US
Kind code	B2
Filing date	Dec 20, 2018
Priority date	Dec 22, 2017
Publication date	Oct 25, 2022
Grant date	Oct 25, 2022

Abstract

The present application relates to compounds of formula (I′) or formula (I), such as formula (Ia), and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing neurodegenerative disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington disease (HD) and other CAG-triplet repeat (or polyglutamine) diseases, amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease), diffuse Lewy body disease, chorea-acanthocytosis, primary lateral sclerosis, multiple sclerosis (MS), frontotemporal dementia, Friedreich's ataxia, acute head injury, and epilepsy (repression of microglia activation).

First claim

The invention claimed is:

1. A compound of formula (I′)

or a pharmaceutically acceptable salt thereof, wherein:
X is selected from —C(O)— and —S(O) 2 —;
R 1 and R 2 each independently is selected from H and C 1-6 alkyl; or R 1 and R 2 taken together with the carbon to which they are attached form a spirocycloalkyl ring;
R 3 is selected from hydroxyl and optionally substituted alkoxy;
R 4 is selected from phenyl, pyridinyl, isoquinolinyl, pyrazinyl, thiophenyl, and thiazolyl; and
wherein R 4 is optionally substituted with one or more R 5 ; and
R 5 , independently for each occurrence, is selected from halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted phenyl, optionally substituted pyrazolyl, optionally substituted pyridinyl, optionally substituted thiazolyl, optionally substituted imidazolyl, optionally substituted pyrimidinyl, optionally substituted isoxazolyl, optionally substituted isothiazolyl, and optionally substituted triazolopyridinyl.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X is —C(O)—.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is pyridinyl optionally substituted with one or more R 5 .

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:
R 4 is substituted with one or more R 5 ;
R 5 , independently for each occurrence, is optionally substituted with one or more R 6 ; and
R 6 , independently for each occurrence, is selected from halogen, CN, oxo, alkyl, alkenyl, alkynyl, alkoxy, alkyl sulfonyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, and heteroaryl.

5. The compound of claim 4 , or a pharmaceutically acceptable salt thereof, wherein R 6 , independently for each occurrence, is selected from halogen, CN, oxo, alkyl, alkoxy, alkyl sulfonyl, and cycloalkyl.

6. A compound of formula (Ia)

or a pharmaceutically acceptable salt thereof, wherein:
R 1 and R 2 each independently is selected from C 1-6 alkyl; or R 1 and R 2 taken together with the carbon to which they are attached form a spirocycloalkyl ring;
R 3 is selected from hydroxyl and optionally substituted alkoxy;
R 5 , independently for each occurrence, is selected from halogen, CN, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkylsulfonyl, optionally substituted alkoxyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted aryl, and optionally substituted heteroaryl; and
p is selected from 0, 1, 2, 3, and 4.

7. The compound of claim 6 , or a pharmaceutically acceptable salt thereof, wherein p is selected from 1 and 2.

8. The compound of claim 6 , or a pharmaceutically acceptable salt thereof, wherein R 5 , independently for each occurrence, is selected from halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted phenyl, optionally substituted pyrazolyl, optionally substituted pyridinyl, optionally substituted thiazolyl, optionally substituted imidazolyl, optionally substituted pyrimidinyl, optionally substituted isoxazolyl, optionally substituted isothiazolyl, and optionally substituted triazolopyridinyl.

9. The compound of claim 6 , or a pharmaceutically acceptable salt thereof, wherein p is 2, and wherein one occurrence of R 5 is —F and the other occurrence of R 5 is —CH(F) 2 .

10. The compound of claim 1 that is

or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1 that is

or a pharmaceutically acceptable salt thereof.

12. The compound of claim 1 that is

or a pharmaceutically acceptable salt thereof.

13. The compound of claim 1 that is

or a pharmaceutically acceptable salt thereof.

14. A pharmaceutical composition comprising (a) a compound of claim 1 ; and (b) a pharmaceutically acceptable excipient.

15. A method of inhibiting a Keap1 protein, comprising contacting a cell with an effective amount of at least one compound of claim 1 .

Assignees

• Medimmune Ltd

Inventors

• Bartholomeus Johan
• Bürli Roland
• Jarvis Rebecca
• Johnstone Shawn
• Ostenfeld Thor
• Terstiege Ina
• Travagli Massimiliano
• Turcotte Stephane

Classifications

• C07D213/61

  Halogen atoms or nitro radicals · CPC title

• C07D417/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• C07D213/54 Primary

  Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title

• C07D401/04 Primary

  directly linked by a ring-member-to-ring-member bond · CPC title